Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron will receive the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.